Kronos BioKRON
KRON
About: Kronos Bio Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery and development of small molecule therapeutics to address deregulated transcription, a hallmark of cancer and autoimmune diseases.
Employees: 8
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
0% more funds holding in top 10
Funds holding in top 10: 2 [Q4 2024] → 2 (+0) [Q1 2025]
1.18% less ownership
Funds ownership: 32.56% [Q4 2024] → 31.38% (-1.18%) [Q1 2025]
15% less capital invested
Capital invested by funds: $18.7M [Q4 2024] → $15.8M (-$2.88M) [Q1 2025]
16% less funds holding
Funds holding: 56 [Q4 2024] → 47 (-9) [Q1 2025]
36% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 14
69% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 13
Research analyst outlook
We haven’t received any recent analyst ratings for KRON.
Financial journalist opinion
Neutral
Business Wire
1 month ago
KRONOS BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kronos Bio, Inc. - KRON
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Kronos Bio, Inc. (NasdaqGS: KRON) to Concentra Biosciences, LLC. Under the terms of the proposed transaction, shareholders of Kronos will receive $0.57 in cash per share plus one non-tradeable contingent value right. KSF is seeking to determine whether this consideration and the process that le.
Neutral
PRNewsWire
1 month ago
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Kronos Bio, Inc. - KRON
NEW YORK , May 1, 2025 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Kronos Bio, Inc. (NASDAQ: KRON ), relating to the proposed merger with Concentra Biosciences, LLC.
Neutral
Business Wire
1 month ago
Shareholder Alert: The Ademi Firm Investigates Whether Kronos Bio, Inc. is Obtaining a Fair Price for Its Public Shareholders
MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating Kronos (Nasdaq: KRON) for possible breaches of fiduciary duty and other violations of law in its transaction with Concentra. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you. In the transaction, shareholders of Kronos will receive only $0.57 per share, plus one contingent value right, which represent.
Neutral
Business Wire
1 month ago
KRON Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Kronos Bio, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Kronos Bio, Inc. (NASDAQ: KRON) to Concentra Biosciences, LLC for $0.57 in cash per share plus one non-tradeable contingent value right is fair to Kronos shareholders. Halper Sadeh encourages Kronos shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com.
Neutral
GlobeNewsWire
1 month ago
Kronos Bio Enters into Agreement to Be Acquired by Concentra Biosciences for $0.57 in Cash per Share Plus a Contingent Value Right
CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. ("Kronos Bio") (Nasdaq: KRON), a biotechnology company that has been developing small molecule therapeutics to address cancers and other diseases driven by deregulated transcription, today announced that it has entered into a definitive merger agreement (the “Merger Agreement”) with Concentra Biosciences, LLC ( “Concentra”), whereby Concentra will acquire Kronos Bio for $0.57 in cash per share of Kronos Bio common stock (“Kronos Bio Common Stock”), plus one non-tradeable contingent value right ("CVR"), which represents the right to receive: (i) 50% of the net proceeds in the case of a disposition of the Company's product candidates known as KB-9558 and KB-7898 that occurs within 2 years following closing; (ii) 100% of the net proceeds in the case of a disposition of the Company's product candidates known as KB-0742, lanraplenib and entospletinib that occurs prior to closing; (iii) 100% of cost savings realized prior to closing; (iv) 80% of cost savings realized between the merger closing date and the second (2nd) anniversary of the merger closing date; and (v) 50% of cost savings realized between the second (2nd) anniversary of the merger closing date and the third (3rd) anniversary of the merger closing date, each pursuant to the contingent value rights agreement (the “CVR Agreement”).
Neutral
GlobeNewsWire
2 months ago
Kronos Bio Reports Fourth Quarter and Full Year 2024 Financial Results
SAN MATEO, Calif., and CAMBRIDGE, Mass., March 18, 2025 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a biopharmaceutical company, today reported fourth quarter and full year 2024 financial results.
Neutral
GlobeNewsWire
6 months ago
Kronos Bio Announces CEO Transition and Reduction in Force
– Norbert Bischofberger, Ph.D., is stepping down from his role as President & CEO – – Deborah Knobelman, Ph.D.
Neutral
GlobeNewsWire
7 months ago
Kronos Bio Highlights Preclinical Data that Show p300 KAT Inhibitors Reduce Inflammation in an Oral Presentation at ACR Convergence 2024
– Preclinical data demonstrate the ability of p300 KAT inhibition to modulate multiple pro-inflammatory signaling pathways, including antibodies and cytokine production, in ex vivo and in vivo models at well tolerated exposures –
Negative
Zacks Investment Research
7 months ago
Kronos Bio, Inc. (KRON) Reports Q3 Loss, Tops Revenue Estimates
Kronos Bio, Inc. (KRON) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to loss of $0.54 per share a year ago.
Neutral
GlobeNewsWire
7 months ago
Kronos Bio Data Presentation at EORTC-NCI-AACR Symposium Highlights the Importance of p300 KAT Inhibition in HPV-Driven Tumors
– Preclinical data demonstrate that inhibiting the p300 KAT domain reactivates p53 in HPV-driven tumors resulting in anti-tumor activity – – Preclinical data demonstrate that inhibiting the p300 KAT domain reactivates p53 in HPV-driven tumors resulting in anti-tumor activity –
Charts implemented using Lightweight Charts™